|
| 36648934 | Challenges and Opportunities for Clinical Trials in Patients With Glioma. | JAMA Neurol | 2023 |
| 37853118 | Clinical trial links oncolytic immunoactivation to survival in glioblastoma. | Nature | 2023 |
| 38024244 | NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. | Neurooncol Adv | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37811539 | Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients. | Neurooncol Adv | 2023 |
| 37722087 | Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. | J Clin Oncol | 2023 |
| 37024595 | Tumor inflammation-associated neurotoxicity. | Nat Med | 2023 |
| 36648934 | Challenges and Opportunities for Clinical Trials in Patients With Glioma. | JAMA Neurol | 2023 |
| 37018498 | Understanding the Genetic Risk of <i>IDH</i>-Mutant Glioma. | N Engl J Med | 2023 |
| 37327319 | Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients. | Clin Cancer Res | 2023 |
| 37322012 | Primary central nervous system lymphoma. | Nat Rev Dis Primers | 2023 |
| 37059069 | Cancer neuroscience: State of the field, emerging directions. | Cell | 2023 |
| 37527941 | Association of <i>MTHFR</i> Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. | Neurology | 2023 |
| 37488293 | Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. | Nat Med | 2023 |
| 38024244 | NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. | Neurooncol Adv | 2023 |
| 37527941 | Association of <i>MTHFR</i> Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. | Neurology | 2023 |
| 37488293 | Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. | Nat Med | 2023 |
| 37853118 | Clinical trial links oncolytic immunoactivation to survival in glioblastoma. | Nature | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37811539 | Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients. | Neurooncol Adv | 2023 |
| 37722087 | Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. | J Clin Oncol | 2023 |
| 37024595 | Tumor inflammation-associated neurotoxicity. | Nat Med | 2023 |
| 37059069 | Cancer neuroscience: State of the field, emerging directions. | Cell | 2023 |
| 37322012 | Primary central nervous system lymphoma. | Nat Rev Dis Primers | 2023 |
| 37018498 | Understanding the Genetic Risk of <i>IDH</i>-Mutant Glioma. | N Engl J Med | 2023 |
| 37327319 | Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients. | Clin Cancer Res | 2023 |
| 34479368 | How I treat neurologic complications in patients with lymphoid cancer. | Blood | 2022 |
| 35911635 | Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma. | Neurooncol Adv | 2022 |
| 35945164 | Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. | Br J Haematol | 2022 |
| 36071927 | Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma. | Neurooncol Adv | 2022 |
| 35353218 | Factors associated with psychological distress in caregivers of patients with malignant gliomas. | Support Care Cancer | 2022 |
| 34633681 | Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. | Cancer | 2022 |
| 34611696 | Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma. | Neuro Oncol | 2022 |
| 34609036 | Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/B<sub>0</sub> -shim array coils at 3â¿¿T. | NMR Biomed | 2022 |
| 34958166 | In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic Imaging. | J Magn Reson Imaging | 2022 |
| 35167655 | Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. | Blood | 2022 |
| 34479368 | How I treat neurologic complications in patients with lymphoid cancer. | Blood | 2022 |
| 34878541 | Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. | Neuro Oncol | 2022 |
| 34751617 | Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. | Radiology | 2022 |
| 35353218 | Factors associated with psychological distress in caregivers of patients with malignant gliomas. | Support Care Cancer | 2022 |
| 35911635 | Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma. | Neurooncol Adv | 2022 |
| 36071927 | Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma. | Neurooncol Adv | 2022 |
| 35945164 | Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. | Br J Haematol | 2022 |
| 34878541 | Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. | Neuro Oncol | 2022 |
| 35167655 | Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. | Blood | 2022 |
| 34958166 | In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic Imaging. | J Magn Reson Imaging | 2022 |
| 34611696 | Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma. | Neuro Oncol | 2022 |
| 34609036 | Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/B<sub>0</sub> -shim array coils at 3â¿¿T. | NMR Biomed | 2022 |
| 34633681 | Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. | Cancer | 2022 |
| 34751617 | Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. | Radiology | 2022 |